Bloom Energy enters the first week of July in a peculiar position — the stock has pulled back 6% on the week yet closed Tuesday up 10%, analysts are raising targets they can't quite reach, and the next earnings catalyst is less than four weeks away.
The most important shift since the previous note is the easing of options defensiveness. The put/call ratio sat at a 52-week high of 1.43 as recently as June 24. It has since retreated to 1.26, just a third of a standard deviation above its 20-day average of 1.23. That unwind suggests the acute hedging demand flagged in the prior article has been absorbed — traders who bought puts into the June volatility have either closed or let positions decay. The options market is no longer signalling distress.
Short positioning remains elevated but is no longer building. The short position dipped modestly to 12.5% of the free float from a recent peak near 13%, trimming about 3.5% on the week. The 30-day build is still 15% — a meaningful accumulation since late May — but the pace has slowed. Borrow conditions offer no meaningful pressure to shorts: the cost to borrow has roughly doubled over the past month but remains low in absolute terms at 0.59%, and availability is exceptionally loose at over 2,000% of outstanding short interest. There is no mechanical squeeze dynamic here.
The analyst picture is one of a Street running to keep pace with a stock that has moved too fast for comfort. Three firms lifted targets on July 1 — UBS to $350, Evercore ISI to $350, and Roth Capital to $285 — all maintaining rather than upgrading. The consensus rating remains at Sell. The mean target of $276 sits well below the current price of $303. That gap is the defining tension: analysts collectively do not endorse this valuation, yet they keep nudging targets higher as the stock moves through them. The bull case rests on surging data-center demand for clean on-site power, a growing backlog, and EPS momentum that ranks in the 98th percentile of the ORTEX universe. The bear case centres on methane-fuel-cell reliance, high customer concentration, and a valuation that is increasingly demanding — the P/E has expanded to roughly 104x and EV/EBITDA to 81x, both elevated against sector peers. Earnings factor scores are exceptional — EPS surprise in the 91st percentile, forward EPS growth in the 100th — but quality metrics remain thin, and the value score is near the bottom of the universe.
Insider selling continues at a steady pace. The COO, Chief Legal Officer, Chief Commercial Officer, and Chief Accounting Officer all sold shares on June 16 at prices near $289. Director John Chambers sold 55,000 shares in late May for roughly $16.4 million. Net insider activity over 90 days is marginally positive by share count due to a CEO award of 80,000 shares in May, but the cash value of sales from operating executives over the same period is substantial. The selling is likely programmatic rather than a directional bet, but the uniform direction — every named executive selling into strength — is worth noting as the stock approaches the Q2 print on July 30.
Closest correlated peers had a volatile week. FCEL surged 21% on the day and 65% on the week — a move that dwarfs Bloom's own activity and likely reflects idiosyncratic news rather than sector-wide re-rating. VRT rose 9% on the day. The divergence across the group makes sector tailwinds a difficult read for Bloom specifically. The July 30 earnings release will test whether the backlog strength and guidance raise that powered the April print — which produced a 23% next-day move and 26% over five days — can be repeated, or whether the stock's already-elevated multiple leaves less room for positive surprise.
See the live data behind this article on ORTEX.
Open BE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
